We caught up with speakers and presenters at a major HIV community meeting to learn how HIV care providers can uncover and remove the harm of bias in their work.
Paul Sax, M.D., recaps dozens of highlights from 9th International AIDS Society Conference on HIV Science.
"At CROI, the 'executive director hat' comes off, and I'm purely a community advocate again," Rob Newells writes. "This year, that was even more true than in previous years."
One study in Amsterdam deployed a strategy to identify acute HIV in men who have sex with men (MSM) and then link newly diagnosed individuals to care.
One factor that could help determine whether a person achieves an undetectable viral load is their health literacy, which is the measure of personal engagement and ability to seek medical care.
First in-human trial results of nanoformulations of efavirenz and lopinavir confirmed the potential for a 50% dose reduction to the current standard oral dose of both antiretrovirals.
Long-acting antiretrovirals: Are they the future of HIV treatment or will the future pass them by? Researcher Charles W. Flexner recently addressed several common myths.
Richard Jefferys analyzes key presentations from this year's Conference on Retroviruses and Opportunistic Infections.
"People who are designing the studies, who are funding the studies, need to make [enrolling women] a priority," says Rena Patel, M.D.
Self-injected monotherapy with PRO 140, a monoclonal antibody that binds to the CCR5 receptor on CD4 cells, maintained viral suppression in 10 of 16 study participants for 41 to 123 weeks.